A Patent Review on SARS Coronavirus Main Protease (3CL\textsuperscript{pro}) Inhibitors

C. S. Brian Chia,*[a] Weijun Xu,[a] and Pearly Shuyi Ng[a]
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is an unprecedented global health emergency causing more than 4.2 million fatalities as of 30 July 2021. Only three antiviral therapies have been approved or granted emergency use authorization by the FDA. The SARS-CoV-2 3CL protease (3CL\textsuperscript{pro}) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis, although no inhibitors have been approved. This patent review discusses SARS coronavirus 3CL\textsuperscript{pro} inhibitors that have been filed up to 30 July 2021, giving an overview on the types of inhibitors that have generated commercial interest, especially amongst drug companies. Insights into the common structural motifs required for active site binding is also discussed.

1. Introduction

In late 2019, a number of severe pneumonia clusters were reported in Wuhan, Hubei province, China\[1,2\]. Genome sequencing revealed the responsible pathogen was a coronavirus with 80\% nucleotide sequence identity to the severe acute respiratory syndrome coronavirus (SARS-CoV), responsible for the 2002–2004 outbreak originating from Foshan, Guangdong province, China\[3–6\]. This new coronavirus was named ‘severe acute respiratory syndrome coronavirus 2’ (SARS-CoV-2) by the International Committee on Taxonomy of Viruses\[7\] and the disease was called ‘coronavirus disease 2019’ (COVID-19) by the World Health Organization (WHO). The virus has since spread globally, infecting more than 196 million people and causing more than 4.2 million deaths as of 30 July 2021\[8\]. Although a number of vaccines have been granted authorization, only three antiviral therapies (Remdesivir, Casirivimab – Imdevimab and Sotrovimab)\[9–11\] have so far been approved or granted emergency use authorization by the United States Food and Drug Administration (FDA), signifying an urgent need for more antiviral drugs.

The coronavirus 3-chymotrypsin-like protease (3CL\textsuperscript{pro}); also known as ‘main protease’ or ‘M\textsuperscript{pro}’) is deemed an attractive drug target due to its essential role in coronavirus polyprotein processing. It cleaves the polyprotein at more than 11 sites to yield essential proteins required for virus replication and pathogenesis\[12–17\]. As 3CL\textsuperscript{pro} has no reported human homologues, a 3CL\textsuperscript{pro} inhibitor should not inhibit any human proteases and hence, reduce the risk of side-effects.\[13,16\] 3CL\textsuperscript{pro} is a cysteine protease with a unique substrate preference for a P1 glutamine, hydrolysing the peptide bond at the C-terminus of glutamine.\[13–16\] Particularly noteworthy is that the 3CL\textsuperscript{pro} of SARS-CoV and SARS-CoV-2 share 96\% amino acid sequence identity so inhibitors designed for the former should work equally well on the latter.\[12,17\] Indeed, the first coronavirus 3CL\textsuperscript{pro} inhibitor to enter clinical trials is Pfizer’s PF-07304814 (ClinicalTrials.gov identifier NCT04535167) in September 2020. First described in a patent filed in 2005 as a SARS-CoV 3CL\textsuperscript{pro} inhibitor (WO 2005/113580), its synthesis, structure-activity relationship study and preclinical development details were published only much later in 2020.\[18\].

2. Patent Review

Although many SARS-CoV and SARS-CoV-2 3CL\textsuperscript{pro} inhibitors have been reported, collated and reviewed in academic journals since the 2002–2004 SARS-CoV pandemic, none have so far been approved as antiviral drugs.\[12–14\] A plausible explanation could be that commercial interest in coronavirus drug development waned rapidly after the SARS-CoV pandemic ended. However, since the start of the SARS-CoV-2 pandemic in late 2019, academic and commercial interest in coronavirus 3CL\textsuperscript{pro} inhibitors returned with a vengeance. This review collates SARS-CoV and SARS-CoV-2 3CL\textsuperscript{pro} inhibitors reported in patent applications since the 2002 SARS-CoV pandemic up to 30 July 2021. SciFinder\textsuperscript{a} software (CAS)\[19\] was employed and search terms: ‘coronavirus 3CL\textsuperscript{pro} inhibitor’, ‘coronavirus 3CL protease inhibitor’, ‘coronavirus Mpro inhibitor’, ‘coronavirus main protease inhibitor’ and ‘coronavirus protease inhibitor’ were used. The patents are summarized in Table 1 in chronological order with detailed analysis included vide infra.

SciFinder\textsuperscript{a} revealed 18 patents on CoV 3CL\textsuperscript{pro} inhibitors and together with a 2020 patent review on coronavirus therapeutic agents,\[20\] a total 24 patents are summarised in Table 1. Unsurprisingly, majority of the patents (23 out of 24) described inhibitors designed to inhibit SARS-CoV 3CL\textsuperscript{pro} as the SARS-CoV-2 pandemic started only in late 2019. However, since both viral proteases share 96\% sequence identity,\[12,17\] inhibitors designed for the former should also inhibit the latter protease. Indeed, Pfizer’s PF-00835231 (6b), first described in WO 2005/113580, was originally designed to inhibit SARS-CoV 3CL\textsuperscript{pro} (IC\textsubscript{50} 4 nM)\[18\] and was later shown to be a potent inhibitor of SARS-CoV-2 3CL\textsuperscript{pro} (IC\textsubscript{50} 8 nM).\[46\]

To our best knowledge, the earliest patent application describing SARS-CoV 3CL\textsuperscript{pro} inhibitors was filed by Pfizer in 2004 (WO 2004/093860; Table 1)\[20\] involving 3-residue peptidomimetics bearing a P1 glutamine or lactam glutamine mimic with a C-terminal electrophilic α,β-unsaturated ester warhead (Figure 1). Some inhibitors had their P3 amino acid residue substituted by a 2-pyridone moiety (1b), presumably to improve their pharmacokinetic properties. All the described compounds were originally designed to inhibit the rhinovirus 3C protease which shares some structural similarity to coronavirus 3CL\textsuperscript{pro}.\[20\] Unfortunately, no coronavirus 3CL\textsuperscript{pro} inhibition data were reported in the patent. We believe this is the first patent describing peptidomimetics bearing a P1 lactam glutamine mimic (1a) used for inhibiting SARS-CoV 3CL\textsuperscript{pro} and were originally designed as rhinovirus 3C protease inhibitors in 1999 by Agouron Pharmaceuticals (WO 99/57135).\[46\] We are currently unable to recommend these peptidomimetics for further drug
Table 1. Summary of SARS coronavirus 3CL\textsuperscript{pro} inhibitor patents in chronological order up to 30 July 2021.

| Patent number | Applicant/Assignee | Filing date (dd.mm.yyyy) | Inhibitor type | Fig. | Ref. |
|---------------|--------------------|--------------------------|----------------|------|------|
| WO 2004/093860 | Pfizer             | 13.04.2004               | peptidomimetic | 1    | [20] |
| WO 2004/101742 | Cytovia            | 06.05.2004               | peptidomimetic | 2    | [21] |
| US 2006/0014821 | Agouron Pharmaceuticals | 13.08.2004 | peptidomimetic | 3    | [22] |
| WO 2005/041904 | Fulcrum Pharmaceuticals | 01.11.2004 | small molecule | 4    | [23] |
| WO 2005/066123 | Taigen Biotechnology | 28.12.2004 | peptidomimetic | 5    | [24] |
| WO 2005/113580 | Pfizer             | 09.05.2005               | peptidomimetic | 6    | [25] |
| US 2006/0019667 | National Health Research Institutes, Taiwan | 20.07.2005 | small molecule | 7    | [26] |
| WO 2006/024278 | Tsinghua University, Shanghai Institute of Organic Chemistry | 24.10.2005 | peptidomimetic | 8    | [27] |
| CN 1965833 A  | Peking University   | 18.11.2005               | small molecule | 9    | [28] |
| WO 2006/061714 | Pfizer             | 06.12.2005               | peptidomimetic | 10   | [29] |
| WO 2006/095624 | Tokyo Medical and Dental University, RIKEN | 01.03.2006 | small molecule | 11   | [30] |
| WO 2007/075145 | Singapore Polytechnic, Shanghai Institute of Materia Medica | 15.12.2006 | small molecule | 12   | [31] |
| CN 103159665B | Tianjin International Joint Academy of Biotechnology and Medicine | 09.12.2011 | small molecule | 13   | [32] |
| WO 2013/049382 | Kansas State University, Ohio State University, Wichita State University | 27.09.2012 | peptidomimetic | 14   | [33] |
| KR 1020130002975 | Chonnam National University | 20.12.2012 | small molecule | 15   | [34] |
| WO 2013/166319 | Kansas State University, Wichita State University | 02.05.2013 | peptidomimetic | 16   | [35] |
| CN 106176728 A | Institute of Microbiology, Chinese Academy of Sciences | 07.07.2016 | small molecule | 17   | [36] |
| WO 2017/114509 | Shanghai Institute of Materia Medica, University of Lübeck | 30.12.2016 | peptidomimetic | 18   | [37] |
| US 2017/0313685 | Purdue Research Foundation | 28.04.2017 | small molecule | 19   | [38] |
| WO 2017/1222935 | Kansas State University, Wichita State University | 16.07.2017 | peptidomimetic | 20   | [39] |
| CN 108785293 A | Tianjin International Joint Academy of Biomedicine | 28.04.2017 | small molecule | 21   | [40] |
| WO 2018/042343 | GSK                | 30.08.2017               | peptidomimetic | 22   | [41] |
| WO 2020/030143 | Shanghai Institute of Materia Medica, Fudan University | 09.08.2019 | peptidomimetic | 23   | [42] |
| WO 2021/176369 | Pfizer             | 03.03.2021               | peptidomimetic | 24   | [43] |

Development until their SARS-CoV-2 3CL\textsuperscript{pro} inhibitory potencies are revealed.

The second earliest patent application on SARS-CoV 3CL\textsuperscript{pro} inhibitors was filed by Cytovia in 2004 (WO 2004/101742; Table 1)\textsuperscript{[21]} describing 2-residue peptidomimetics containing a P1 glutamine residue with a C-terminal electrophilic monofluoromethylketone warhead (Figure 2). P1 alanine, glycine and N-dimethylated glutamine mimics were also exemplified although their inhibitory activities were not disclosed. Compound 2b was revealed to be the most potent inhibitor with an EC\textsubscript{50} of 0.02 μg/mL in a SARS-CoV Vero cell assay. No biochemical 3CL\textsuperscript{pro} inhibition (IC\textsubscript{50}) data were reported in the patent. A publication was found for 2e containing a P1 N-dimethylated glutamine with an EC\textsubscript{50} of 2.5 μM in a SARS-CoV-

Brian Chia obtained his B.Sc. with first-class honours and a Ph.D. from the University of Adelaide followed by postdoctoral training at Cambridge University, UK. In 2005, he joined the Institute of Molecular and Cell Biology before becoming a group leader at the Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR). He has co-authored more than 50 research papers and is an inventor/co-inventor of 8 granted or pending patents involving small molecules, peptides and peptidomimetics with antibacterial, anticancer, antifungal and antiviral properties.

Weijun Xu obtained his B.Sc. with first-class honours in Biochemistry and a Ph.D. from the University of Queensland followed by postdoctoral training at the University of California, San Diego. He lectured at the Singapore Polytechnic School of Chemical and Life Sciences for 8 years before his current position at the Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR) as a senior research fellow. His research interests include computational biology, modelling of protein–ligand and protein–protein interactions including GPCRs, proteases and kinases inhibitors.

Pearly S. Ng is a medicinal chemist who has been involved in the development of various novel small molecule therapeutics for infectious diseases in the past decade. Prior to being a medicinal chemist, she spent 6 years as a research chemist in various companies working on diversity-oriented synthesis and parallel synthesis technologies. She obtained her Ph.D. in organic chemistry from Nanyang Technological University and has co-authored several research publications in medicinal and organic chemistry. She is also a co-inventor of 3 patent applications.
Vero cell assay. The authors revealed that the P1 glutamine residue was incompatible with the C-terminal electrophilic warhead due to intramolecular cyclisation with the P1 glutamine side-chain primary amide, resulting in bioactivity loss. To solve this problem, Pfizer filed a patent in 2004 describing peptidomimetic inhibitors where the P1 glutamine was modified to either 5- or 6-membered lactams (WO 2004/093860; Figure 1a).

Notably, this P1 modification strategy was adopted in subsequent patents involving coronavirus 3CLpro peptidomimetic inhibitors after 2004. In addition, the idea of incorporating a 2-pyridone moiety at the P3 position, exemplified in compound 2f, was reported in an earlier Pfizer patent (WO 2004/093860; Figure 1b). Although there are currently no follow-up publications for 2f, this idea was later adopted for peptidomimetic ketoamide SARS-CoV-2 3CLpro inhibitors in a 2020 Science paper.

The third earliest patent on coronavirus 3CLpro inhibitors was filed in 2004 by Agouron Pharmaceuticals involving 1-, 2- and 3-residue peptidomimetics bearing a P1 5-membered lactam glutamine mimic with a C-terminal electrophilic α,β-unsaturated ester warhead (US 2006/0014821; Table 1). 8 structures were exemplified (Figure 3) but no biochemical 3CLpro inhibition (IC₅₀) data were reported in the patent. A structure search on all 8 compounds, including compounds 3c to 3f, revealed no follow-up publications. Notably, peptidomimetics with α,β-unsaturated ester warheads inhibiting SARS-CoV 3CLpro were described in an earlier patent (WO 2004/093860; Figure 1). We are currently unable to gauge their potential for further antiviral drug development due to the lack of inhibitory potency data. Interestingly, another patent involving peptidomimetic inhibitors with electrophilic α,β-unsaturated ester warheads was filed in 2004 by Taigen Biotechnology (WO 2005/066123; Figure 5), discussed vide infra.

The fourth earliest patent was filed in 2004 by Fulcrum Pharmaceuticals involving small molecules containing one or two boronic acid moieties (WO 2005/041904; Table 1). 403 structures were described. The strongest binder was identified to be compound 4b, also named FL-166, with a SARS-CoV 3CLpro Kᵢ of 22 nM, followed by 4c to 4f with Kᵢ values.

![Figure 1. General scaffolds from WO 2004/093860.](image1)

![Figure 2. Structures from WO 2004/101742. (a) general scaffold; (b–f) exemplified structures.](image2)

![Figure 3. Structures from US 2006/0014821. (a,b) general scaffolds; (c–f) exemplified structures.](image3)

![Figure 4. Structures from WO 2005/041904. (a–e) exemplified structures with the most potent Kᵢs against SARS-CoV 3CLpro.](image4)

![Figure 5. Structures from WO 2005/066123. (a) general scaffold; (b–f) exemplified structures.](image5)
ranging between 3.5 and 6.9 μM (Figure 4). Compounds 4b, 4c and 4d were reported in a research article to possess Ks of 0.04, 4.5 and 16 μM against SARS-CoV 3CLpro respectively.\[45\] No SARS-CoV-2 3CLpro inhibition data have been reported for these compounds using SciFinder® structure searches. In our view, cell-based EC50 values should first be obtained for 4a to gauge its potential for further development as an antiviral drug.

The fifth patent was filed in 2004 by Taigen Biotechnology involving 3-residue peptidomimetics containing a P1 5-membered lactam glutamine mimic with a C-terminal electrophilic α,β-unsaturated ester warhead (WO 2005/066123; Table 1)\[24\] 145 compounds were reported and 77 were disclosed to be sub-micromolar SARS-CoV 3CLpro inhibitors. Unfortunately, no Ks or IC50 values were assigned to any of the structures. However, a literature search revealed compound 5b, also named TG-0203770, to be the strongest binder with a SARS-CoV 3CLpro Ks of 58 nM, followed by 5c and 5d (Ks 0.66 and 2.26 μM respectively; Figure 5).\[30\] Compound 5c was later reported to inhibit SARS-CoV-2 3CLpro with an IC50 of 286 nM.\[51\] In contrast, 5d was reported to be a weak SARS-CoV 3CLpro inhibitor (IC50 85 μM)\[31\] suggesting that a P2 phenylalanine should be avoided in the design of new SARS-CoV 3CLpro inhibitors. Compounds 5e and 5f, known as TG-0205486 and TG-0204998 respectively, were reported with Ks of 99 and 38 nM respectively.\[32\] Notably, two earlier patents involving electrophilic α,β-unsaturated ester warhead peptidomimetics were filed by Pfizer and Agouron Pharmaceuticals (WO 2004/093860 and US 2006/0014821), discussed vide supra. We opine compounds 5b, 5e and 5f warrant further investigation as SARS-CoV-2 drug candidates.

The sixth earliest patent was filed in 2005 by Pfizer involving 2-residue peptidomimetics containing a P1 5-membered lactam glutamine mimic with a C-terminal electrophilic hydroxymethylketone warhead (WO 2005/113580; Table 1)\[25\] 61 compounds were reported with 35 exhibiting sub-micromolar IC50s against SARS-CoV 3CLpro. A literature search revealed PF-00835231 (6b; Figure 6) as the lead candidate with a very potent IC50 of 4 nM against SARS-CoV 3CLpro and a SARS-CoV EC50 of 4.8 μM in a SARS-CoV infection cellular assay while a recent paper reported an IC50 of 8 nM against SARS-CoV-2 3CLpro.\[45\] This strongly suggests that inhibitors designed to inhibit SARS-CoV 3CLpro can be repurposed for SARS-CoV-2 3CLpro as both proteases share 96% sequence identity.\[12,13\] The phosphate prodrug of PF-0835231 entered phase 1 clinical trials in September 2020 to evaluate safety and pharmacokinetics in hospitalised COVID-19 patients (ClinicalTrials.gov identifier: NCT04353167). Notably, substituting the P2 leucine with phenylalanine resulted in a 25-fold activity loss (IC50 103 vs. 4 nM; 6e and 6b respectively), suggesting that the SARS-CoV 3CLpro S2 binding pocket preferred smaller sized residues.\[18\] N-methylating the P2 leucine resulted in a 20-fold activity loss (IC50 83 vs. 4 nM; 6f and 6b respectively), suggesting that the P2 NH plays an important role in 3CLpro binding.\[16\] 6-membered lactam glutamine mimics were also described in the patent but none were exemplified.

The seventh earliest patent was filed in 2005 by the National Health Research Institutes, Taiwan, involving small molecules from a commercially available small molecule library screen (US 2006/0019967; Table 1)\[21\] 21 compounds were reported to possess inhibitory activities with 4 exhibiting 'very low' micromolar IC50s against SARS-CoV 3CLpro (compounds 7a to 7d; Figure 7). Unfortunately, IC50 values were not disclosed in the patent. A literature search revealed compound 7a to be the most potent with an IC50 of 300 nM against SARS-CoV 3CLpro.\[51\] The next most potent is 7b with an IC50 of 900 nM while 7c to 7f exhibited IC50s between 3 to 10 μM.\[53\] Structure searches revealed there are currently no reports on their SARS-CoV-2 3CLpro inhibitory activities. Interestingly, compound 7c, also known as PNU-136592, was earlier reported by Pharmacists to inhibit Mru8, a bacteria enzyme involved in cell wall peptidoglycan biosynthesis.\[54\] In our view, cell-based EC50 values should first be obtained to gauge their potential for further antiviral drug development.

The eighth earliest patent was filed in 2005 by Tsinghua University and the Shanghai Institute of Organic Chemistry involving 3- and 4-residue peptidomimetics bearing a P1 5-membered lactam glutamine mimic with a C-terminal electrophilic α,β-unsaturated ester warhead (WO 2006/042478; Table 1)\[31\] 10 compounds were exemplified and no IC50 data was reported (Figure 8). The patent is written in Chinese and an English version could not be found online. A research article published in the same month of patent filing reported inhibitors 8b and 8d (named N1 and N3 respectively) with Ks of 10.7 and 9.0 μM against SARS-CoV 3CLpro respectively.\[55\]

![Figure 6. Structures from WO 2005/113580. (a) general scaffold; (b–f) exemplified structures.](image1.png)

![Figure 7. Six most potent SARS-CoV 3CLpro inhibitors reported in US 2006/0019967.](image2.png)
2020 Nature paper reported 8d/N3 to be a very potent SARS-CoV-2 3CLpro inhibitor and that its Ki could not be feasibly measured.\(^\text{[15]}\) No SARS-CoV-2 3CLpro inhibition data have been reported so far for compounds 8c and 8e using SciFinder\textsuperscript® structure searches. In our opinion, 8d/N3 warrants further investigation as an antiviral drug.

The ninth earliest patent was filed in 2005 by Peking University involving the discovery of the oral H\textsubscript{1} histamine receptor antagonist oxatomide possessing SARS-CoV 3CLpro inhibitory activity (CN 1965833 A; Figure 9).\(^\text{[28]}\) No IC\textsubscript{50} or Ki data was reported. The patent is written in Chinese and no English version could not be found online. A SciFinder\textsuperscript® structure search did not reveal any academic journals reporting its SARS-CoV 3CLpro inhibitory activity. Due to the lack of inhibitory data, we are currently unable to gauge its potential for further development as an antiviral drug.

The tenth earliest patent was filed in 2005 by Pfizer involving 2- and 3-residue peptidomimetics containing P1 5-membered lactam and tertiary amide glutamine mimics with C-terminal electrophilic aldehyde or ketone warheads (WO 2006/061714; Table 1).\(^\text{[29]}\) 15 compounds were exemplified with 4 (10b to 10e; Figure 10) exhibiting sub-micromolar IC\textsubscript{50}s against SARS-CoV 3CLpro. Ketone peptidomimetic 10f exhibited a moderate IC\textsubscript{50} of 2.3 \(\mu\text{M}\), suggesting that aldehyde warheads are much more reactive than ketones. Compound 10d has been resynthesized and reported to inhibit SARS-CoV-2 3CLpro with an IC\textsubscript{50} of 8.5 nM.\(^\text{[56]}\) Aldehydes are known to be highly reactive towards endogenous biological nucleophiles, potentially rendering compounds 10b to 10e cytotoxic. Aldehydes are also metabolically unstable due to their susceptibility to oxidation and reduction by liver enzymes.\(^\text{[57,58]}\) Hence, we believe aldehyde peptidomimetics lack potential for further drug development due to their metabolic liabilities.

The eleventh earliest patent was filed in 2006 by Tokyo Medical and Dental University and RIKEN involving small molecules with a 3-cyanopyridine scaffold (WO 2006/095624; Table 1; Figure 11).\(^\text{[30]}\) 102 compounds were described. The patent is published in Japanese and no English version can be found online. To our best knowledge, 3CLpro IC\textsubscript{50} inhibition data was not reported in the patent. Structure searches using SciFinder\textsuperscript® did not reveal any follow-up journal publications. Due to the lack of inhibitory data, we are unable to gauge their potential for further drug development.

The twelfth earliest patent was filed in 2006 by Singapore Polytechnic and Shanghai Institute of Materia Medica involving small molecules with a chromone (1,4-benzopyrone) scaffold (WO 2007/075145; Table 1).\(^\text{[31]}\) 17 structures were exemplified and 4 compounds, 12b to 12e (Figure 12), were reported with SARS-CoV 3CLpro IC\textsubscript{50}s ranging from 24 to 49 \(\mu\text{M}\). These compounds were published in a research article in the same year of patent filing.\(^\text{[59]}\) Due to their weak inhibitory activities, we opine that these compounds are not potent enough for further drug development.
The thirteenth earliest patent was filed in 2011 by Tianjin International Joint Academy of Biotechnology and Medicine involving 2,3-dioxindole SARS-CoV 3CL\textsuperscript{pro} inhibitors (CN 103159665B; Table 1).\cite{32} The patent is written in Chinese and an English version could not be found online. 3 structures (Figure 13) were exemplified with SARS-CoV 3CL\textsuperscript{pro} IC\textsubscript{50}s between 20 to 88 μM. Structure searches on the compounds using SciFinder\textsuperscript{®} did not reveal any follow-up journal publications. In our opinion, these compounds are not potent enough to be developed as antiviral drugs.

The fourteenth patent was filed in 2012 by Kansas State, Ohio State and Wichita State Universities involving 2- and 3-residue peptidomimetics containing a P1 5-membered lactam glutamine mimic with a C-terminal electrophilic aldehyde or ketoamide warhead (WO 2013/049382; Table 1).\cite{33} A hydroxymethyl sulfonic acid prodrug masking the reactive aldehyde warhead was also described (14c; Figure 14). Compounds 14b, 14c and 14d exhibited IC\textsubscript{50}s ranging between 3.5 to 4.7 μM in a SARS-CoV 3CL\textsuperscript{pro} biochemical assay. No SARS-CoV 3CL\textsuperscript{pro} IC\textsubscript{50}s were reported for tripeptide aldehyde 14e and ketoamide 14f in the patent but were later reported in a research article (0.23 and 0.61 μM respectively).\cite{66} Compounds 14b and 14c, also named GC373 and GC376 respectively, were reported to inhibit SARS-CoV 3CLpro with 3.5 and 4.4 μM IC\textsubscript{50} in a research paper.\cite{35} Interestingly, 14b/GC373 was shown to be much more active against SARS-CoV-2 3CL\textsuperscript{pro}, exhibiting an IC\textsubscript{50} of 0.042 μM in a recent paper.\cite{44} Similarly, 14c/GC376 was also shown to be much more active against SARS-CoV-2 3CL\textsuperscript{pro}, exhibiting IC\textsubscript{50} ranging between 0.03 to 0.62 μM.\cite{45,62,63} We opine ketoamide peptidomimetics 14d and 14f can potentially be further developed as SARS-CoV-2 3CL\textsuperscript{pro} antivirals because ketoamide peptidomimetic protease inhibitors such as Boceprevir and Telaprevir have been approved for treating hepatitis C virus infections.\cite{64}

The fifteenth earliest patent was filed in 2012 by Chonnam National University, South Korea revealing that the plant flavonoid, quercetin (KR 1020130002975; Table 1; Figure 15), was able to inhibit SARS-CoV 3CL\textsuperscript{pro} with an IC\textsubscript{50} of 73 μM and suggested that it could potentially be used to treat SARS-CoV infections. The patent is written in Korean and no English version could be found online. In our opinion, we believe that its inhibitory activity is too weak to be considered for development as an antiviral drug.

The sixteenth earliest patent was filed in 2013 by Kansas State and Wichita State Universities involving 3-residue cyclic peptidomimetics and linear piperidine-2,6-dione peptidomimetics with C-terminal aldehyde or ketoamide warheads (WO 2013/166319; Table 1).\cite{34} Although SARS-CoV 3CL\textsuperscript{pro} IC\textsubscript{50}s were not disclosed in the patent, a research article by the inventors reported compound 16c (Figure 16) inhibited SARS-CoV 3CL\textsuperscript{pro} with an IC\textsubscript{50} of 15.5 μM.\cite{65} No SARS-CoV-2 3CL\textsuperscript{pro} inhibitory activities have so far been reported for compounds 16c to 16i. In our view, 16c lacks potency for further drug development.

The seventeenth earliest patent was filed in 2016 by The Institute of Microbiology, Chinese Academy of Sciences involving small molecule disulphide SARS-CoV-3 3CL\textsuperscript{pro} inhibitors (CN 106176728 A; Table 1).\cite{56} The patent is written in Chinese and an English version could not be found online. 12 structures were exemplified and the 5 most potent compounds possess IC\textsubscript{50}s between 1.3 to 2.2 μM (17b to 17f; Figure 17). A SciFinder\textsuperscript{®} structure search revealed one follow-up academic paper reporting their SARS-CoV 3CL\textsuperscript{pro} inhibitory activities.\cite{66} There are currently no reports on SARS-CoV-2 3CL\textsuperscript{pro} inhibitory activities. We opine that these compounds lack drug development potential due to their disulphide moiety, reported to be

Figure 13. Structures from CN 103159665B. (a) general scaffold; (b–f) exemplified structures.

Figure 14. Structures from WO 2013/049382. (a) general scaffold; (b–f) exemplified structures.

Figure 15. Structure of quercetin from KR 1020130002975.

Figure 16. Structures from WO 2013/166319. (a,b) general scaffolds; (c–i) exemplified structures.
unstable in physiological conditions due to the presence of biological reducing agents, free thiols and isomerases.\(^9\)\(^,\)\(^10\) Hence, pharmacokinetic studies should be conducted first before these compounds can be evaluated further.

The eighteenth patent was filed in 2016 by Shanghai Institute of Materia Medica and the University of Lübeck involving 2- and 3-residue peptidomimetics bearing a P1 5-membered lactam glutamine mimic and a C-terminal electrophilic aldehyde warhead (WO 2017/114509; Table 1).\(^{15(1)}\) 74 structures were described with SARS-CoV 3CL\(^{\text{pro}}\) IC\(_{50}\) ranging from 30 nM to 7.4 \(\mu\)M. The four most potent structures are shown in Figure 18 (compounds 18b to 18e) with SARS-CoV 3CL\(^{\text{pro}}\) IC\(_{50}\) ranging from 30 to 100 nM. The most potent inhibitor 18b is structurally similar to Pfizer’s 10b (Figure 10), differing at the P2 residue. 18b’s SARS-CoV 3CL\(^{\text{pro}}\) inhibitory activity is 1.5-fold weaker than Pfizer’s 10b (IC\(_{50}\) 30 and 20 nM respectively), suggesting that SARS-CoV 3CL\(^{\text{pro}}\) prefers a P2 leucine over phenylalanine. This distinction is an important consideration when designing new coronavirus 3CL\(^{\text{pro}}\) inhibitors and may be the reason why a P2 leucine was selected for Pfizer’s lead compound PF-00835231 (Figure 6b).\(^{18}\) 18b was also reported to be the most potent SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitor (IC\(_{50}\) 34 nM) amongst 13 peptide aldehydes in a recent publication,\(^{19}\) suggesting that inhibitors designed for SARS-CoV 3CL\(^{\text{pro}}\) can be effectively used to inhibit SARS-CoV-2 3CL\(^{\text{pro}}\). Interestingly, the addition of a P3 valine to 18b to yield tripeptide aldehyde 18d resulted in an approximate 2-fold activity reduction for SARS-CoV and SARS-CoV-2 3CL\(^{\text{pro}}\) (IC\(_{50}\) 30 to 50 nM and 34 to 68 nM respectively).\(^{18(6)}\) Notably, all the inhibitors described in the patent possess highly electrophilic aldehyde warheads which are known to be highly reactive towards endogenous biological nucleophiles, potentially rendering them cytotoxic. Aldehydes are also metabolically unstable due to their susceptibility to oxidation and reduction by liver enzymes.\(^{57,58}\) Hence, we believe these aldehyde peptidomimetics lack potential for further drug development.

The nineteenth earliest patent was filed in 2017 by Purdue Research Foundation involving small molecules with amido-phenyl scaffolds (US 2017/0313685; Table 1).\(^{18(3)}\) 77 structures were reported with SARS-CoV 3CL\(^{\text{pro}}\) IC\(_{50}\) between 0.8 to 27.3 \(\mu\)M. The five most potent inhibitors were identified to be compounds 19b to 19f (Figure 19) with 0.8 to 2.0 \(\mu\)M IC\(_{50}\). Interestingly, the structure of compound 19f was reported in an earlier 2015 research paper with an IC\(_{50}\) of 1.9 \(\mu\)M against HKU4-CoV 3CL\(^{\text{pro}}\).\(^{59}\) There are currently no reports on their SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitory activities. We opine that the most potent inhibitor, 19b, should be further evaluated for drug development.

The twentieth earliest patent was filed in 2017 by Kansas State and Wichita State Universities involving dipeptide peptidomimetics with a P1 5-membered lactam glutamine analog and a C-terminal hydroxymethyl sulfonic acid prodrug warhead against the Middle East Respiratory Syndrome (MERS) coronavirus 3CL\(^{\text{pro}}\) (WO 2017/222935; Table 1).\(^{20}\) The hydroxymethyl sulfonic acid moiety changes to a reactive electrophilic aldehyde warhead at physiological pH, first described in WO 2013/049382.\(^{33}\) Although no SARS-CoV 3CL\(^{\text{pro}}\) inhibitory activities were disclosed, the MERS-CoV and SARS-CoV-2 3CL\(^{\text{pro}}\) share approximately 50% sequence identity\(^{18(6)}\) so inhibitors designed to inhibit MERS-CoV 3CL\(^{\text{pro}}\) will likely be able to inhibit SARS-CoV-2 3CL\(^{\text{pro}}\). 8 compounds were described with IC\(_{50}\) ranging from 0.3 to 3.1 \(\mu\)M with compounds 20b to 20f being the most
potent against MERS-CoV 3CL\(^{\text{pro}}\) (Figure 20). There are currently no reports on their SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitory activities. As the hydroxymethyl sulfonic acid moiety transforms into a reactive aldehyde warhead in physiological conditions, we opine these compounds lack drug development potential as explained \textit{vide supra}.

The twenty-first earliest patent was filed in 2017 by Tianjin International Joint Academy of Biomedicine revealing that the N-methyl-D-aspartate (NMDA) receptor antagonist and gamma aminobutyric acid (GABA) receptor modulator, acamprosate calcium (Figure 21), was able to inhibit SARS-CoV 3CL\(^{\text{pro}}\) (CN 108785293 A; Table 1).\(^{[40]}\) The patent is written in Chinese and no English version could be found online. Unfortunately, no IC\(_{50}\) or \(K_i\) value was reported and there are no follow-up reports in academic journals. Hence, we are currently unable to comment on its drug development potential for treating COVID-19.

The twenty-second patent was filed by GSK in 2017 involving 3-residue peptidomimetics containing a P1 5-membered lactam glutamine mimic with a C-terminal electrophilic ketoamide warhead (WO 2018/042343; Table 1).\(^{[41]}\) 48 structures were described with SARS-CoV 3CL\(^{\text{pro}}\) IC\(_{50}\) of approximately 7 nM. The five most potent inhibitors against SARS-CoV 3CL\(^{\text{pro}}\) are shown in Figure 22. There are currently no reports on their SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitory activities based on a SciFinder® search. In our opinion, these compounds can potentially be developed as SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitors to treat COVID-19 as oral ketoamide peptidomimetic protease inhibitors such as Boceprevir and Telaprevir have been approved for treating hepatitis C virus infections.\(^{[64]}\)

A special note is also made for WO 2020/030143 (Table 1), filed by Shanghai Institute of Materia Medica and Fudan University in 2019.\(^{[42]}\) It involves 2-residue peptidomimetics bearing a P1 5- or 6-membered lactam glutamine mimic with a C-terminal electrophilic ketoamide warhead designed to inhibit MERS-CoV 3CL\(^{\text{pro}}\). The patent is written in Chinese and the English version could not be found online. No SARS-CoV or SARS-CoV-2 3CL\(^{\text{pro}}\) IC\(_{50}\) data were reported in the patent. However, this patent is included in this review as the MERS-CoV and SARS-CoV-2 3CL\(^{\text{pro}}\) share approximately 50\% sequence identity\(^{[16]}\) so inhibitors designed to inhibit MERS-CoV 3CL\(^{\text{pro}}\) will likely be able to inhibit SARS-CoV-2 3CL\(^{\text{pro}}\). 253 compounds were described with IC\(_{50}\) ranging from sub-nanomolar to 786 nM using a MERS pseudovirus neutralization assay. The five most potent MERS-CoV 3CL\(^{\text{pro}}\) inhibitors, 23b to 23f, possess sub-nanomolar to 5 nM IC\(_{50}\) (Figure 23). There are currently no reports on their SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitory activities based on a SciFinder® search. In our opinion, these compounds can potentially be developed as SARS-CoV-2 3CL\(^{\text{pro}}\) inhibitors to treat COVID-19 as oral ketoamide peptidomimetic protease inhibitors such as Boceprevir and Telaprevir have been approved for treating hepatitis C virus infections.\(^{[64]}\)

The final patent in this review is an application patent involving 13 peptidomimetic protease inhibitors (WO 2021/176369; Table 1).\(^{[43]}\) Interestingly, 6 peptidomimetics with various C-terminal electrophilic warheads have been described in an earlier patent (WO 2005/113580),\(^{[25]}\) all bearing a P1 5-membered lactam glutamine mimic. No 3CL\(^{\text{pro}}\) inhibitory data
were disclosed in the patent but SARS-CoV 3CL\textsuperscript{pro} IC\textsubscript{50}s for compounds 24b to 24e (Figure 24) were reported in a recent research paper.\textsuperscript{[16]} Surprisingly, the patent also described the peptidomimetic rhinovirus 3C protease inhibitor, Rupintrivir (24f), as a potential COVID-19 therapeutic despite its lack of SARS-CoV-2 3CL\textsuperscript{pro} inhibitory activity.\textsuperscript{[17]} Three hepatitis C and human immunodeficiency virus protease inhibitors were also described; Filibuvir (24g), Nelfinavir (24h) and AG-1859 (24i). No IC\textsubscript{50}s were reported in the patent but a literature search revealed Nelfinavir to possess weak SARS-CoV-2 3CL\textsuperscript{pro} inhibitory activity (IC\textsubscript{50} 41.5 μM).\textsuperscript{[70]} In our view, the peptidomimetic hydroxymethylketones 24b and 24c possess the highest potential for further drug development if converted to a phosphate prodrug as observed for clinical candidate PF-00835231 (6b).\textsuperscript{[18]} In contrast, we opine that Rupintrivir (24f) and Nelfinavir (24h) are not potent enough for further development. We are unable to comment on the drug development potential for Filibuvir (24g) and AG-1859 (24i) due to the lack of SARS-CoV-2 3CL\textsuperscript{pro} inhibitory data.

Lastly, a special mention is made for Pfizer’s oral SARS-CoV-2 3CL\textsuperscript{pro} peptidomimetic inhibitor PF-07321332 (Figure 25) which entered phase 3 clinical trials in July 2021 for treating non-hospitalised SARS-CoV-2 infected adults (ClinicalTrials.gov identifier NCT04960202).\textsuperscript{[71]} Like previous Pfizer 3CL\textsuperscript{pro} inhibitor patents, it bears a P1 5-membered lactam glutamine mimic and interestingly, a nitrile warhead not described in any patents found in this review. This is particularly intriguing as nitrile warhead peptidomimetics have been reported to be relatively weak SARS-CoV 3CL\textsuperscript{pro} inhibitors with IC\textsubscript{50}s ranging between 4.6 to 49 μM.\textsuperscript{[72]} To our best knowledge, there are currently no published reports on its SARS-CoV-2 3CL\textsuperscript{pro} IC\textsubscript{50} and a SciFinder\textsuperscript{®} structure search did not reveal any patents for PF-07321332.

3. Summary and Outlook

24 patents describing coronavirus 3CL\textsuperscript{pro} inhibitors have so far been filed up to 30 July 2021 (Table 1). 9 of the patents were filed by pharmaceutical companies while the remaining 15 from academia. 10 of the 24 patents described inhibitors that have not been reported in academic journals. 14 of the 24 patents involved peptidomimetics with electrophilic warheads, signifying that this modality has generated more commercial interest compared to small molecules. A plausible reason could be that warhead peptidomimetics generally show more potent inhibitory activities, typically in the nanomolar range, compared to small molecules. In addition, warhead peptidomimetics have been successfully developed into antiviral drugs, exemplified by the hepatitis C virus protease inhibitors Boceprevir and Telaprevir.\textsuperscript{[64]}

The peptidomimetic inhibitors covered in this review bear a P1 5- of 6-membered lactam glutamine-mimicking residue first described by Agouron Pharmaceuticals in 1999 (WO 99/57135).\textsuperscript{[46]} Reported P2 residues ranged from leucine to cyclohexylalanine and phenylalanine, suggesting that the SARS-CoV S2 subsite could accommodate bulky residues with 6-membered side-chains. However, a 2020 research paper by Pfizer revealed that a P2 leucine exhibited 11- and 25-fold IC\textsubscript{50} improvement over cyclohexylalanine and phenylalanine respectively, suggesting that leucine was highly preferred at the P2 position.\textsuperscript{[16]} Indeed, Pfizer utilised a P2 leucine in their phosphate prodrug of PF-00835231 (6b) which entered phase 1 clinical trials in September 2020 (ClinicalTrials.gov identifier: NCT04535167). Other plausible P2 residue substitutions include norvaline and t-butylalanine (Figure 24). The P3 position is more accommodating to different moieties including indoles (Figures 6, 10 and 18), amino acid residues like threonine (Figure 3), valine (Figures 5 and 8) and naphthylalanine (Figures 14 and 22). The longest peptidomimetic inhibitor in this review constituted 4 residues (Figure 8) but unfortunately, no IC\textsubscript{50}s were reported as it would be interesting to study the correlation of peptidomimetic length to inhibition potency.

Small molecule inhibitors constituted 10 of the 24 patents (Table 1). In contrast to the peptidomimetic inhibitors, their reported IC\textsubscript{50}s or K\textsubscript{s} were generally inferior (close to or above 1 μM), with the exception of two patents filed by Fulcrum Pharmaceuticals and the National Health Research Institutes, Taiwan (Table 1; Figures 4 and 7 respectively). The former
described a small molecule containing two boronic acid moieties (K 22 nM) and the latter, a biphenyl sulphine (IC50 300 nM). In our view, both warrant further investigations into their drug development potential.

We believe this review serves to bolster the knowledge of existing coronavirus 3CLpro inhibitors reported beyond academic journals and the general structural motifs required for binding and inhibiting SARS-CoV-2 3CLpro. We are hopeful that some of these inhibitors will be successfully developed and approved as drugs for treating COVID-19.

**Abbreviations**

3CLpro 3-chymotrypsin-like protease  
CoV coronavirus  
COVID-19 coronavirus disease 2019  
EC50 half-maximal effective concentration  
FDA Food and Drug Administration  
GABA gamma aminobutyric acid  
IC50 half-maximal inhibitory concentration  
MERS Middle East Respiratory Syndrome  
Mpro main protease  
NMDA N-methyl-D-aspartate  
SARS severe acute respiratory syndrome  
WHO World Health Organization

**Acknowledgements**

This review was supported by the Agency for Science, Technology and Research (A*STAR).

**Conflict of Interest**

The authors declare no conflict of interest.

**Keywords:** 3CLpro · Mpro · SARS-CoV-2 · cysteine protease inhibitor · COVID-19

[1] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan, *N. Engl. J. Med.* 2020, 383(13), 737. DOI: 10.1056/NEJMoA2001017.

[2] Q. Li, X. Guan, P. Wu, X. Wang, L. Zhong, Y. Tong, R. Chen, K. S. M. Leung, E. Y. Y. Lau, J. Y. Wong, X. Xing, N. Xiang, *N. Engl. J. Med.* 2020, 382(13), 1196. DOI: 10.1056/NEJMoA2001316.

[3] T. G. Ksiazek, D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. G. Rollin, P. M. R. RSurve, J. J.1. Landers, R. H. Martin, J. S. Teekay, T. Leis, C. P. M. Murphy, F. G. Markoff, N. M. Zasada, W. H. McLean, D. E. Thompson, M. A. L. Massa, B. L. Bhakdi, B. G. Br J. Med. Libr. Assoc. 2018, 106(4), 588. DOI: 10.5195/jmla.2018.515.

[4] S. A. Fuhrman, D. A. Matthews, A. K. Patick, P. A. Rejto (Pfizer Inc.), *J. Med. Chem.* 2004, 47(10), 2132. DOI: 10.1021/jm0304610.

[5] R. L. Hoffman, R. S. Kania, A. M. Brothers, J. F. Davies, R. A. Ferre, K. S. Gajiwala, M. He, R. J. Hogan, K. Kozminski, L. Li, J. W. Lockner, J. Lou, M. T. Marra, L. J. Mitchell Jr., B. W. Murray, J. A. Nieman, S. Noell, S. P. Planken, T. Rowe, K. Ryan, G. J. Smith, J. E. Solowiej, C. M. Steppan, B. Taggart, *J. Med. Chem.* 2020, 63(21), 12725. DOI: 10.1021/acs.jmedchem.0c00163.

[6] A. K. Ghosh, M. Brindisi, D. Shahabi, M. E. Chapman, A. D. Mesecar, ChemMedChem, 2020, 15, 907. DOI: 10.1002/cmdc.202002223.

[7] R. L. Hoffman, R. S. Kania, M. A. Brothers, J. F. Davies, R. A. Ferre, K. S. Gajiwala, M. He, R. J. Hogan, K. Kozminski, L. Li, J. W. Lockner, J. Lou, M. T. Marra, L. J. Mitchell Jr., B. W. Murray, J. A. Nieman, S. Noell, S. P. Planken, T. Rowe, K. Ryan, G. J. Smith, J. E. Solowiej, C. M. Steppan, B. Taggart, *J. Med. Chem.* 2020, 63(21), 12725. DOI: 10.1021/acs.jmedchem.0c00163.
D. Kim, H. Ryu, T. Hanh, S. Hwang (Chonnam National University), KR 1020130002957, 2012.

K. Chang, Y. Kim, W. C. Groutas (Kansas State University, Wichita State University), 2013/166319, 2013.

L. Zhang, S. Fang, H. Dai, Q. Wang (Institute of Microbiology, Chinese Academy of Sciences), CN 106176728 A, 2016.

H. Yang, K. Zhou, C. Hu, Z. Wang, C. Chen, W. Xu, H. Jiang, J. Chen, D. Ma, M. Bartlam, Z. Rao, PLoS Biol. 2005, 3(10), e324. DOI: 10.1371/journal.pbi.0030324.

S. E. St. John, A. D. Mesecar (Purdue Research Foundation), WO 2017/0313685, 2017.

L. Zhang, J. Li, C. Luo, H. Liu, W. Xu, G. Chen, O. W. Liew, W. Zhu, C. M. Puah, X. Shen, H. Jiang, Biog. Med. Chem. 2006, 14(24), 8295. DOI: 10.1016/j.bmcm.2006.09.014.

A. M. Prior, Y. Kim, S. Weerasekara, M. Moroze, K. R. Alliston, R. A. Z. Uy, W. C. Groutas, K. Chang, Sci. Transl. Med. 2013, 23, 6317. DOI: 10.1010/nrd4050.

Y. Kim, S. Lovell, K. Tiew, S. R. Mandadapu, K. R. Alliston, K. P. Battaile, W. C. Groutas, K. Chang, J. Virol. 2012, 86(21), 11754. DOI: 10.1128/JVI.01348–12.

C. Ma, M. Sacco, B. Hurst, J. A. Townsend, Y. Hu, T. Szeoto, X. Zhang, B. Tarbet, M. T. Marty, Y. Chen, J. Wang, Cell Res. 2020, 30, 678. DOI: 10.1038/s41422-020-0356-z.

A. D. Rathnayake, J. Zheng, Y. Kim, K. D. Perera, S. Mackin, D. K. Meyerholz, M. M. Kushkipathy, K. P. Battaile, S. Lovell, S. Perlman, W. C. Groutas, K. Chang, Sci. Transl. Med. 2020, 12(557), eabc5332. DOI: 10.1126/scitranslmed.aabc5332.

M. P. Manns, T. von Hahn, Nat. Rev. Drug Discovery 2013, 12, 595. DOI: 10.1038/nrd4050.

S. R. Mandadapu, P. M. Weeratunga, A. M. Prior, R. A. Z. Uy, S. Aravapalli, K. R. Alliston, G. H. Lushington, Y. Kim, D. H. Hua, K. Chang, W. C. Groutas, Biog. Med. Chem. Lett. 2013, 23, 3709. DOI: 10.1016/j.bmcl.2013.05.021.

L. Wang, B. Bao, G. Song, C. Chen, X. Zhang, W. Lu, Z. Wang, Y. Cai, S. Li, S. Fu, Song, H. Yang, J. Wang, Eur. J. Med. Chem. 2017, 137, 450. DOI: 10.1016/j.ejmech.2017.05.045.

A. Gori, P. Gagni, S. Rinaldi, Chem. Eur. J. 2017, 23(60), 14987. DOI: 10.1002/chem.201703199.

W. Dai, D. Jochmans, H. Xie, H. Yang, J. Li, H. Su, D. Chang, J. Wang, J. Peng, L. Zhu, Y. Nian, R. Hilgenfeld, H. Jiang, H. Shr, C. Li, Y. Huang, L. Chang, J. Hsu, C. J. Peters, A. H. Wang, M. Hsu, J. Med. Chem. 2006, 49(16), 4971. DOI: 10.1021/jm0603926.

J. Shi, J. Fang, T. Kuo, C. Kuo, P. Liang, H. Huang, Y. Wu, J. Jan, Y. E. Cheng, C. Wong, Biog. Med. Chem. 2005, 13, 5240. DOI: 10.1021/jm050056s.

C. Lee, C. Kuo, T. Ko, M. Hsu, Y. Tsai, C. Chang, S. Yang, S. Chen, H. Chen, M. Hsu, S. Shih, P. Liang, A. H. Wang, J. Biol. Chem. 2009, 284(12), 7646. DOI: 10.1074/jbc.M807947200.

I. Lu, N. Mahindroo, P. Liang, Y. Peng, C. Kuo, K. Tsai, H. Hsieh, Y. Chao, S. Wu, J. Med. Chem. 2006, 49(17), 5154. DOI: 10.1021/jm0602070.

R. W. Sarver, J. M. Rogers, D. E. Epps, J. Biomol. Screening 2002, 7(1), 21. DOI: 10.1177/10870571020070104.

H. Yang, W. Xie, X. Xue, K. Yang, J. Ma, W. Liang, Q. Zhao, Z. Zhou, D. Pei, J. Ziebuhr, R. Hilgenfeld, K. Y. Yuen, L. Wong, G. Gao, S. Chen, Z. Chen, D. Ma, M. Bartlam, Z. Rao, PLoS Biol. 2005, 3(10), e324. DOI: 10.1371/journal.pbi.0030324.